NDC 0074-7096

Qulipta

Atogepant

Qulipta is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Abbvie Inc.. The primary component is Atogepant.

Product ID0074-7096_3e500acd-4915-4477-bf46-7284b3591bc2
NDC0074-7096
Product TypeHuman Prescription Drug
Proprietary NameQulipta
Generic NameAtogepant
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2021-09-30
Marketing CategoryNDA /
Application NumberNDA215206
Labeler NameAbbVie Inc.
Substance NameATOGEPANT
Active Ingredient Strength30 mg/1
Pharm ClassesCalcitonin Gene-related Peptide Receptor Antagonist [EPC], Calcitonin Gene-related Peptide Receptor Antagonists [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 0074-7096-04

4 TABLET in 1 BOTTLE (0074-7096-04)
Marketing Start Date2021-10-06
NDC Exclude FlagN
Sample Package?Y

Drug Details

NDC Crossover Matching brand name "Qulipta" or generic name "Atogepant"

NDCBrand NameGeneric Name
0074-7094QuliptaAtogepant
0074-7095QuliptaAtogepant
0074-7096QuliptaAtogepant

Trademark Results [Qulipta]

Mark Image

Registration | Serial
Company
Trademark
Application Date
QULIPTA
QULIPTA
90133079 not registered Live/Pending
ALLERGAN SALES, LLC
2020-08-24

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.